{"id":192656,"date":"2026-08-10T11:17:59","date_gmt":"2026-08-10T05:47:59","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=192656"},"modified":"2026-08-10T11:17:59","modified_gmt":"2026-08-10T05:47:59","slug":"ngl-fine-chem-ltd-share-price-near-52-week-high-2026-08-10-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ngl-fine-chem-ltd-share-price-near-52-week-high-2026-08-10-2\/","title":{"rendered":"NGL Fine-Chem Ltd. (NGLFINE) Share Price Within 2% of 52-Week High"},"content":{"rendered":"<style id=\"univest-disable-toc\">#ez-toc-container,.ez-toc-container,.lwptoc,.toc_container,.wp-block-rank-math-toc-block{display:none!important}<\/style>\n<p style=\"margin-top:0!important;margin-bottom:0!important;\"><a href=\"https:\/\/univest.in\/stocks\/nglfine\/ngl-fine-chem-ltd-share-price-today\">NGL Fine-Chem Ltd.<\/a> Share Price stands at Rs 3,487.80, with the stock trading within 2% of its 52-week high. Market capitalisation is Rs 2,118.60 crore.<\/p>\n<p style=\"margin-top:0!important;\">NGL Fine-Chem Ltd. Share Price is at Rs 3,487.80 at the time of the Univest screener qualification, placing the stock within 2% of its 52-week high. With a market capitalisation of Rs 2,118.60 crore, the move is notable because it puts the company close to its one-year peak and naturally draws attention to valuation, profitability and sector positioning.<\/p>\n<p>The verified data confirms the price event, but it does not establish a company-specific catalyst behind the move. Even so, NGL Fine-Chem Ltd. Share Price trading near its yearly high matters because such setups often push investors to recheck whether operating quality, returns ratios and relative valuation still justify the interest. In this case, the company sits in the Healthcare sector and the Pharmaceuticals &amp; Drugs industry, where comparisons with industry medians provide useful context.<\/p>\n<p>For readers tracking NGL Fine-Chem Ltd. Share Price Today, the present setup is less about speculation and more about understanding how a Rs 2,118.60 crore pharmaceutical company is being valued when its P\/E stands at 44.02, its P\/B is 6.43, and its return ratios remain stronger than many industry benchmarks tracked by Univest.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"NGL_Fine-Chem_Ltd_Share_Price_Today_Within_2_of_52-Week_High\"><\/span><strong>NGL Fine-Chem Ltd. Share Price Today: Within 2% of 52-Week High<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>LTP at 2% Qualification<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 3,487.8<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,118.6 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>52-Week High Position<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Trading within 2% of its 52-week high<\/td>\n<\/tr>\n<\/table>\n<p>NGL Fine-Chem Ltd. (NGLFINE) traded at Rs 3,487.8. Reported volume was 191.<\/p>\n<p>NGL Fine-Chem Ltd. Share Price Today is Rs 3,487.80, which is also the exact last traded price recorded when the Univest screener identified the stock as trading within 2% of its 52-week high. That matters because proximity to a 52-week high often puts a stock on more investor watchlists, especially when the move appears in a sector where valuations and profitability can vary sharply across listed names.<\/p>\n<p>In this case, the supplied data confirms the event itself rather than a breakout or a new high. That distinction is important. The stock is close to its one-year peak, but the data does not say it crossed that reference level. For market participants, this is still an important signal because stocks trading in this zone are often assessed for whether momentum is being supported by fundamentals, industry standing and consistency in returns ratios.<\/p>\n<p>NGL Fine-Chem Ltd. Share Price also stands out because the company\u2019s market capitalisation of Rs 2,118.60 crore places it above the industry median market cap of Rs 142.30 crore and the industry average of Rs 477.72 crore in the same industry benchmark set. That means the market is already assigning the business a scale premium relative to a large portion of the Pharmaceuticals &amp; Drugs universe.<\/p>\n<p>As Univest tracks these near-52-week-high screens, the next logical step is to move from price attention to business quality and valuation discipline through a closer look at NGL Fine-Chem Ltd. Share Price and the company\u2019s underlying financial profile.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"NGL_Fine-Chem_Ltd_NGLFINE_Fundamental_Analysis\"><\/span><strong>NGL Fine-Chem Ltd. (NGLFINE) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,118.6 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">44.02x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">6.43x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">27.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">33.91%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 77.9<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Book Value Per Share<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 532.92<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0.05%<\/td>\n<\/tr>\n<\/table>\n<p>NGL Fine-Chem Ltd. was valued at a P\/E ratio of 44.02x, a P\/B ratio of 6.43x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.<\/p>\n<p>Profitability and capital efficiency were represented by ROE of 27.9% and ROCE of 33.91%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.<\/p>\n<p>Per-share and shareholder-return metrics included EPS of Rs 77.9, book value per share of Rs 532.92, dividend yield of 0.05%. Dividend yield is a current or historical ratio and does not guarantee future distributions.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Pharmaceuticals &amp; Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">44.02x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.11x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">60.11x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0x to 3,417.8x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">6.43x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">1.82x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">27.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">9.89%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">33.91%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">12.62%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,118.6 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 142.3 crore<\/td>\n<\/tr>\n<\/table>\n<p>NGL Fine-Chem Ltd. (NGLFINE) is classified under sector: Healthcare and industry: Pharmaceuticals &amp; Drugs.<\/p>\n<p>NGL Fine-Chem Ltd. (NGLFINE) has a P\/E ratio of 44.02x, which is above the benchmark median of 18.11x, a difference of +143.07%. P\/E is a valuation multiple and is not, by itself, a buy or sell signal.<\/p>\n<p>NGL Fine-Chem Ltd. (NGLFINE) has a ROE of 27.9%, which is above the benchmark median of 9.89%, a difference of +182.1%. NGL Fine-Chem Ltd. (NGLFINE) has a ROCE of 33.91%, which is above the benchmark median of 12.62%, a difference of +168.7%.<\/p>\n<p>Track stocks reaching yearly peaks through the <a href=\"https:\/\/univest.in\/screeners\/52-week-high\">Univest 52-week-high screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/venusrem\/venus-remedies-ltd-share-price-today\"><strong>Venus Remedies Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">VENUSREM-BE<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,068.61<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.81<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">3.01<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">9.85<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">7.89<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/hesterbio\/hester-biosciences-ltd-share-price-today\"><strong>Hester Biosciences Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">HESTERBIO<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,057.85<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15.11<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.52<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16.17<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14.12<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/fredun\/fredun-pharmaceuticals-ltd-share-price-today\"><strong>Fredun Pharmaceuticals Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">FREDUN<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,057.67<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">46.96<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">7.01<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">11.42<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/sakar\/sakar-healthcare-ltd-share-price-today\"><strong>Sakar Healthcare Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">SAKAR<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,057.34<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">56.99<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">6.15<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">11.88<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/indoco\/indoco-remedies-ltd-share-price-today\"><strong>Indoco Remedies Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">INDOCO<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,045.45<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">363.31<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2.04<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.85<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15.67<\/td>\n<\/tr>\n<\/table>\n<p>NGL Fine-Chem Ltd. (NGLFINE) has a P\/E ratio of 44.02x compared with the displayed peer median of 46.96x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.9% compares with a peer median of 11.88% across the companies shown in the table. ROCE stood at 33.91% versus the displayed peer median of 13.16%, providing a capital-efficiency comparison. NGL Fine-Chem Ltd. (NGLFINE) has a market capitalisation of Rs 2,118.6 crore. Among the 5 peers shown, 0 have a larger market capitalisation.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching_NGL_Fine-Chem_Ltd\"><\/span><strong>Why Investors Are Watching NGL Fine-Chem Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>NGL Fine-Chem Ltd. Share Price is Rs 3,487.80, and the stock has been identified by the Univest screener as trading within 2% of its 52-week high.<\/li>\n<li>The company\u2019s market capitalisation of Rs 2,118.60 crore is far above the same industry median of Rs 142.30 crore and average of Rs 477.72 crore.<\/li>\n<li>Valuation is premium, with P\/E at 44.02 and P\/B at 6.43, both above industry medians of 18.11 and 1.82 respectively.<\/li>\n<li>Profitability is strong, with ROE of 27.90 and ROCE of 33.91, comfortably ahead of industry medians and the supplied peer set.<\/li>\n<li>Peer comparison shows NGL Fine-Chem Ltd. delivers better return ratios than several similarly sized pharmaceutical companies.<\/li>\n<li>Univest data indicates a near-52-week-high setup that keeps attention on whether premium valuation remains aligned with operating quality.<\/li>\n<\/ul>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"About_NGL_Fine-Chem_Ltd\"><\/span><strong>About NGL Fine-Chem Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>NGL Fine-Chem Ltd. operates in the Healthcare sector and is classified under the Pharmaceuticals &amp; Drugs industry. That places the company in a segment where investors usually focus on product quality, manufacturing consistency, return ratios, earnings resilience and relative valuation versus listed peers. In the current market context, NGL Fine-Chem Ltd. Share Price is being assessed not only as a price event but also as a pharmaceutical business with measurable financial performance.<\/p>\n<p>The supplied data does not expand into product categories or segment-wise revenue lines, so the most reliable company context here is its industry position. Within the same-industry benchmark of 139 companies, NGL Fine-Chem Ltd. stands out for having a relatively high market capitalisation of Rs 2,118.60 crore, along with stronger profitability than many peers and benchmark medians. That combination explains why NGL Fine-Chem Ltd. Share Price is receiving attention as it trades close to its yearly high.<\/p>\n<p>For investors and market watchers, the company currently sits at an intersection of premium valuation, strong return ratios and rising market focus inside the Pharmaceuticals &amp; Drugs space.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Track_NGL_Fine-Chem_Ltd_Share_Price_on_Univest\"><\/span><strong>Track NGL Fine-Chem Ltd. Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/nglfine\/ngl-fine-chem-ltd-share-price-today\">NGL Fine-Chem Ltd. (NGLFINE) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/52-week-high\">Univest 52-week-high screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, yearly-high lists and related market analysis.<\/p>\n<p>Users tracking NGL Fine-Chem Ltd. Share Price on Univest can follow live share price updates, 52-week levels, valuation ratios, profitability metrics and broader market insights in one place. That helps investors compare NGL Fine-Chem Ltd. Share Price Today with the company\u2019s P\/E, P\/B, ROE, ROCE, EPS, book value and market capitalisation without separating the price move from the financial context.<\/p>\n<p>Univest also helps users monitor how NGL Fine-Chem Ltd. Share Price is positioned relative to sector benchmarks and listed peers in Pharmaceuticals &amp; Drugs. For a stock trading near its one-year high, that broader context can be useful in understanding whether market attention is being supported by superior returns ratios, scale within the industry and comparative valuation metrics.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_NGL_Fine-Chem_Ltd_Share_Price_today\"><\/span><strong>What is NGL Fine-Chem Ltd. Share Price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> NGL Fine-Chem Ltd. Share Price today is Rs 3,487.80, which is also the price recorded when the Univest screener qualified the stock as trading within 2% of its 52-week high. The company\u2019s market capitalisation stands at Rs 2,118.60 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_NGL_Fine-Chem_Ltd_Share_Price_in_focus\"><\/span><strong>Why is NGL Fine-Chem Ltd. Share Price in focus?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> NGL Fine-Chem Ltd. Share Price is in focus because the stock is trading within 2% of its 52-week high. That places it near its one-year peak and shifts investor attention toward valuation, profitability, peer positioning and industry benchmarks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_NGL_Fine-Chem_Ltd_trading_near_its_52-week_high\"><\/span><strong>Is NGL Fine-Chem Ltd. trading near its 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, the Univest screener identifies NGL Fine-Chem Ltd. as trading within 2% of its 52-week high. The supplied data confirms proximity to the yearly high zone, with the last traded price recorded at Rs 3,487.80.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_the_valuation_ratios_say_about_NGL_Fine-Chem_Ltd\"><\/span><strong>What do the valuation ratios say about NGL Fine-Chem Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> NGL Fine-Chem Ltd. trades at a P\/E of 44.02 and a P\/B of 6.43. Both are above the same-industry medians of 18.11 and 1.82, indicating the stock is valued at a premium to typical benchmark levels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_profitable_is_NGL_Fine-Chem_Ltd_compared_with_its_industry\"><\/span><strong>How profitable is NGL Fine-Chem Ltd. compared with its industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company reports ROE of 27.90 and ROCE of 33.91. These are well above the same-industry medians of 9.89 and 12.62, showing materially stronger capital efficiency than the broader Pharmaceuticals &amp; Drugs benchmark sample.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_per-share_fundamentals_for_NGL_Fine-Chem_Ltd\"><\/span><strong>What are the key per-share fundamentals for NGL Fine-Chem Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> NGL Fine-Chem Ltd. reports earnings per share of Rs 77.90 and book value per share of Rs 532.92. Its dividend yield is 0.05, which indicates a relatively small payout compared with the current share price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_NGL_Fine-Chem_Ltd_compare_with_similar-sized_peers\"><\/span><strong>How does NGL Fine-Chem Ltd. compare with similar-sized peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Against peers such as Venus Remedies, Hester Biosciences, Fredun Pharmaceuticals, Sakar Healthcare and Indoco Remedies, NGL Fine-Chem Ltd. has stronger ROE and ROCE. Its market capitalisation of Rs 2,118.60 crore is also broadly similar to this comparison group.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_sector_and_industry_does_NGL_Fine-Chem_Ltd_belong_to\"><\/span><strong>Which sector and industry does NGL Fine-Chem Ltd. belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> NGL Fine-Chem Ltd. belongs to the Healthcare sector and the Pharmaceuticals &amp; Drugs industry. The relevant industry benchmark here covers 139 companies, while the wider healthcare sector dataset spans 201 listed companies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NGL Fine-Chem Ltd. Share Price trades within 2% of its 52-week high at Rs 3,487.8. Market cap stands at Rs 2,118.6 crore.<\/p>\n","protected":false},"author":29,"featured_media":192655,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-192656","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["192655"],"rank_math_title":["NGL Fine-Chem Ltd. Share Price and Fundamental Analysis"],"rank_math_description":["NGL Fine-Chem Ltd. Share Price trades within 2% of its 52-week high. Check price action, valuation, profitability, sector and peer analysis."],"rank_math_focus_keyword":["NGL Fine-Chem Ltd. Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/NGL_Fine_Chem_Ltd_NGLFINE_Share_Price_Within_2_of_52_Week_High_bullish-1.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=192656"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192656\/revisions"}],"predecessor-version":[{"id":192657,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192656\/revisions\/192657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/192655"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=192656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=192656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=192656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}